Moreover, although PTEN’s mutations aren’t prominent, its loss frequency is approximately 30–40% in BC, accounting for about 25% in HER2+ BC (Zhang H. Y. et al., 2013; Veeraraghavan et al., 2017). This evidence concerns the gene PTEN and breast cancer.